Healthy Lens & Vision with Age

Healthy Lens & Vision with Age: A Nutrition and Natural-Health Reference

1. Definition and Overview

Visual function undergoes progressive, predictable changes across the adult lifespan. As individuals age, it is normal to notice changes in vision, and the risk for certain eye diseases and conditions increases with advancing years. The concept of "healthy lens and vision with age" encompasses the range of structural and functional changes that occur in the eye from midlife onward, spanning both the normal physiological trajectory of aging and the spectrum of common age-related conditions that can accelerate or exceed that trajectory. Age-related changes occur in all ocular tissues.

The primary age-related concerns that define this field are:

• Presbyopia — progressive loss of near-focusing ability
• Cataract — clouding of the crystalline lens
• Age-related macular degeneration (AMD) — deterioration of the central retina
• Dry eye disease — reduced tear quality and quantity with age
• Vitreous changes — liquefaction of the gel-like interior of the eye

2. Anatomy and Body Systems Involved

2.1 The Crystalline Lens

The lens bends to focus light and form images on the retina at the back of the eye, and this flexibility allows vision at different distances—up close or far away. The human eye relies on the dynamic interplay among the ciliary body, zonular fibers, and crystalline lens for accommodation. In youth, the crystalline lens is supple and malleable, enabling it to alter its shape in reaction to ciliary muscle contraction.

To adjust for near vision, the lens must "round up" from its unaccommodated shape. This shape change is made possible when the ciliary muscles contract, drawing together the tissues that surround the lens in a sphincter-like motion. In response, the body of the lens assumes a more rounded shape, altering the radius of curvature mainly at the anterior surfaces. The accommodation response reduces the focal length of the lens to allow clear focusing of near objects on the retina.

2.2 Multi-Tissue Changes with Age

With advancing age, the cornea flattens and there is an attrition of endothelial cells; the shape of the trabecular meshwork changes and there is a loss of trabecular endothelium; the lens grows and becomes cataractous; the ciliary body becomes collagenized, there are choroidal vascular changes, and Bruch's membrane thickens.

Retinal vessels become hyalinized and there is a loss of rods before cones in the macula. Retinal pigment epithelium (RPE) morphometric changes occur with aging. The vitreous becomes liquefied and there is a loss of vitreous compartmentalization. The sclera becomes rigid and may become calcified. The optic nerve also exhibits structural changes with age.

Common age-related problems at the eye surface include dry eye, the major age-related disease of the lens is cataract, and in the retina, aging is frequently accompanied by macular degeneration. With age, the jelly-like vitreous body that fills the central cavity of the eye liquefies and is able to pull away from its natural attachments to the neural retina, which can lead to the presence of floaters but is also associated with sight-threatening retinal detachment.

3. Key Conditions in the "Healthy Lens and Vision with Age" Spectrum

3.1 Presbyopia

Presbyopia is a common, age-related condition that progressively reduces the eye's ability to focus on close objects, affecting nearly all adults older than 40. As global demographics evolve towards an aging population, the prevalence of presbyopia and its effects on quality of life and visual function are becoming progressively more substantial.

The lens hardens with age; this change may begin as early as the 20s, but can come so gradually it may take decades to notice. Eventually, age-related stiffening and clouding of the lens affects just about everyone. The resulting difficulty focusing on up-close objects is called presbyopia.

3.2 Cataract

The major causes of age-related vision loss can be traced to changes to the structure and function of the lens. Age-related nuclear cataracts, which are caused by aggregation and condensation of proteins, diminish vision because they impede the transmission and focusing of light on the retina.

More than 24 million Americans have cataracts. By age 75, more than half will have had them. Some cataracts stay small and have little effect on eyesight, but others become large and interfere with vision. Symptoms include blurriness, difficulty seeing well at night, lights that seem too bright, and faded color vision.

Opacity of the lens is a direct result of oxidative stress. Cataracts occur primarily due to age, but are also common in diabetes, where superoxide in the mitochondria is elevated as a result of hyperglycemia.

3.3 Age-Related Macular Degeneration (AMD)

Age-related macular degeneration (AMD) is a complex eye disorder and the leading cause of incurable blindness worldwide in the elderly. Clinically, AMD initially affects the central area of the retina known as the macula and is classified as early to late stage (advanced AMD). Advanced AMD is classified into the nonexudative or atrophic form (dry AMD) and the exudative or neovascular form (wet AMD). More severe vision loss is typically associated with the wet form.

A 2014 meta-analysis of pooled global population-based studies of persons between 45 and 85 years of age estimated a prevalence of 8.69% for any AMD. The prevalence of early AMD and late AMD were 8.01% and 0.37%, respectively.

Age-related cellular and metabolic imbalance are made worse by the creation of excessive amounts of free radical species, which causes mitochondrial malfunction. As a result, in AMD-affected eyes, the continued proliferation of oxidative stress caused by systemic antioxidant capacity depletion leads to deprivation of melanocytes, cellular dysfunction, and eventually atrophy within the retinal tissue.

4. Contributing and Associated Risk Factors

4.1 Non-Modifiable Factors

Evidence for strong genetic involvement in AMD susceptibility came from familial aggregation studies and twin studies. The heritability of late AMD is estimated to be up to 71%, which is higher than most complex age-related diseases, including coronary artery disease.

Dysregulation in genetic contribution to AMD is established at 46–71% of disease contribution, with CFH and ARMS2/HTRA1 being the two most notable risk loci among the 103 identified AMD-associated loci so far.

Findings from epidemiological studies have shown that age-related eye disorders often run in families, indicating a genetic component in their development.

4.2 Modifiable Lifestyle Factors

AMD is a multifaceted disease affected by a wide variety of modifiable and non-modifiable risk factors. Primary modifiable risk factors include smoking, having a high body mass index, excessive sunlight exposure, alcohol usage, oxidative changes, a high-fat diet, and an inadequate intake of dietary antioxidants. Hypertension, atherosclerosis, a family history of AMD, advanced age, cataract surgery, cardiovascular disease, increased plasma fibrinogen, diabetes, and genetics are additional risk factors.

Chronic cigarette smoking is the most consistently proven lifestyle risk factor for AMD. Smoking exhibits a dose-response relationship with AMD incidence, as demonstrated by multiple prospective cohort studies. Mechanistic studies indicate that polycyclic aromatic hydrocarbons from tobacco smoke induce oxidative stress, disrupt retinal-choroidal oxygen homeostasis, accelerate drusen deposition, and promote choroidal neovascularization, thereby exacerbating macular degeneration.

Smoking is also a well-documented risk factor for cataracts. The oxidative stress caused by smoking can damage the proteins and fibers in the lens, leading to clouding. Studies have shown that smokers are significantly more likely to develop cataracts than non-smokers.

Excessive alcohol consumption is associated with an increased risk of cataracts. Alcohol can induce oxidative stress and deplete antioxidants in the body, contributing to lens damage. Prolonged exposure to UV radiation from sunlight can also increase the risk of cataracts, as UV rays can damage the proteins in the lens and promote oxidative stress.

Smoking (current and former), physical inactivity, and prolonged sunlight exposure, as well as conditions such as diabetes, hypertension, cardiovascular disease, and obesity, have all been associated with an increased risk of early AMD and its progression.

4.3 Oxidative Stress as a Central Mechanism

Oxidative damage initiated by light penetration into the eye is a significant contributing factor to cataract formation. UV irradiation can cause photochemical generation of reactive oxygen species (ROS), which leads to oxidative damage. Multiple genetic factors, lipid metabolism, oxidative stress, and aging all play a role in the etiology of AMD.

5. Nutrients Studied in Relation to Lens and Vision Health

5.1 Lutein and Zeaxanthin

What They Are

Lutein, zeaxanthin, and meso-zeaxanthin are the only carotenoids found in the human macula and may have a role in visual function. These carotenoids are reported to protect the retina, and thus vision, as antioxidants and by acting as a blue light filter.

Macular pigments have a unique distribution within the retina. Concentrations of lutein (L), zeaxanthin (Z), and meso-zeaxanthin (MZ) are highest in the macula, especially in the center (the fovea). While zeaxanthin has a peak concentration in the central fovea, lutein predominates in the periphery. The ratio of L to Z in the fovea is approximately 1:2.4. Moving eccentrically from the fovea to the periphery, zeaxanthin concentrations decline rapidly while lutein levels slowly rise. In the periphery, the ratio of L to Z reverses, exceeding 2:1.

Scientific Evidence

Observational studies have reported that increased dietary intake and higher serum levels of lutein and zeaxanthin are associated with lower risk of age-related macular degeneration, especially late AMD. Randomized, placebo-controlled clinical trials have demonstrated that xanthophyll supplementation increases macular pigment levels, improves visual function, and decreases the risk of progression to late AMD, especially neovascular AMD.

The highest-quality evidence comes from the AREDS and AREDS2 trials conducted by the National Eye Institute. The Age-Related Eye Disease Studies (AREDS and AREDS2) established that dietary supplements can slow progression of AMD, the most common cause of blindness in older Americans. The original AREDS study, launched in 1996, showed that a dietary supplement formulation containing 500 mg vitamin C, 400 IU vitamin E, 2 mg copper, 80 mg zinc, and 15 mg beta-carotene could significantly slow the progression of AMD from moderate to late disease.

The AREDS study demonstrated that daily high-dose supplementation with antioxidant vitamins and zinc lowered the 5-year odds of progression to late AMD by 28%. Building on these results, the Age-Related Eye Disease Study 2 (AREDS2) evaluated the additional effects of lutein, zeaxanthin, and omega-3 long-chain polyunsaturated fatty acids in 4,203 participants at high risk for advanced AMD.

In AREDS2, begun in 2006, researchers compared the beta-carotene formulation to one with 10 mg lutein and 2 mg zeaxanthin instead. Like beta-carotene, lutein and zeaxanthin are antioxidants with activity in the retina. At the end of the five-year AREDS2 study period, the researchers concluded that lutein and zeaxanthin did not increase risk for lung cancer, and that the new formulation could reduce the risk of AMD progression by about 26%.

Long-term follow-up study of the AREDS2 cohort confirmed that lutein/zeaxanthin was an appropriate replacement for beta-carotene in AREDS2 supplements. Beta-carotene usage nearly doubled the risk of lung cancer, whereas there was no statistically significant increased risk with lutein/zeaxanthin. When compared with beta-carotene, lutein/zeaxanthin had a potential beneficial association with late AMD progression.

A meta-analysis of 20 randomized controlled trials assessed these effects on macular pigment optical density (MPOD). Twenty RCTs involving 938 AMD patients and 826 healthy subjects were identified. Xanthophyll carotenoid supplementation was associated with a significant increase in MPOD in AMD patients (weighted mean difference [WMD] 0.07; 95% CI, 0.03 to 0.11) and in healthy subjects (WMD 0.09; 95% CI, 0.05 to 0.14).

A 2021 systematic review on MPOD concluded that MPOD increased with lutein/zeaxanthin intake, particularly at higher doses, among adults with healthy eyes. The effects of lutein/zeaxanthin intake at doses below 5 mg/day or from dietary sources alone is less clear.

With respect to cataracts, lutein and zeaxanthin are dietary xanthophylls that are components of the macular pigment; their peak absorption spectra help to attenuate oxidative damage by filtering out blue and UV light.

Evidence strength: Strong for slowing progression in established AMD (AREDS2 RCT, large multicenter trial). Moderate-to-strong for increasing macular pigment optical density (multiple RCTs, meta-analyses). Weaker for primary prevention in the general population and for cataract prevention specifically.

5.2 Vitamins C and E

Scientific Evidence

Vitamins A, C, and E are recognized as among the most effective nutrients for reducing the risk of macular degeneration. Vitamin A is essential for RPE cells of the human retina, while vitamins C and E are known to act as antioxidants.

In the AREDS trial, the supplemental formulation included 500 mg vitamin C, 80 mg zinc oxide, 2 mg cupric oxide, and 400 international units vitamin E daily. This combination was shown to reduce AMD progression risk by approximately 25–28% in high-risk individuals.

When assessing the link between vitamin C and E supplement consumption and cataract risk, unmeasured lifestyle differences may account for identified differences in epidemiological studies, as opposed to the consumption of these vitamins alone. Further research is necessary to resolve the lack of cohesion in the current literature concerning the benefit—or lack thereof—of vitamin C and E consumption, to allow for evidence-based recommendations for antioxidant cataract prevention.

Evidence strength: Strong when combined with zinc as part of the AREDS formulation for AMD progression in intermediate-to-advanced AMD. Mixed and insufficient for cataract prevention from vitamin C and E supplementation alone.

5.3 Zinc

Scientific Evidence

Zinc is concentrated in the retina and RPE and was a key component of both the AREDS and AREDS2 formulas. Among participants at the highest risk for AMD, 34% who had taken the antioxidants plus zinc and copper (AREDS formula) progressed to advanced AMD, compared to 44% who had taken the placebo.

In AREDS2, investigators also tested a lower zinc dose (25 mg vs. 80 mg). The hazard ratio for low versus high zinc was 1.04 (95% CI, 0.94–1.14; P = .49), suggesting no statistically significant difference between the two zinc doses over the follow-up period.

Evidence strength: Strong when used in combination with antioxidant vitamins for AMD risk reduction in those with intermediate AMD (large RCT, AREDS). The optimal dose remains an area of ongoing investigation.

5.4 Omega-3 Fatty Acids (DHA and EPA)

Scientific Evidence

The NEI launched AREDS2 in 2006 to test if adding omega-3 fatty acids or lutein + zeaxanthin would make the AREDS formula more effective. Omega-3 fatty acids are produced by plants, including algae, and are present in oily fish such as salmon.

In the AREDS2 trial, adding omega-3 fatty acids or lutein + zeaxanthin to the AREDS formula had no additional overall effect on the risk of advanced AMD. However, observational data have suggested an association between dietary omega-3 intake and AMD risk. Studies have revealed higher consumption of omega-3 fatty acids is associated with significantly lower rates of macular degeneration.

DHA (docosahexaenoic acid) is a structural component of retinal photoreceptor membranes. Omega-3 fatty acid has been found to be useful in ameliorating subjective symptoms of dry eye due to its anti-inflammatory properties.

Evidence strength: Moderate from observational studies linking dietary omega-3 to lower AMD risk. Negative from the AREDS2 RCT for supplemental omega-3 in addition to the baseline AREDS formula. Promising but preliminary for dry eye disease.

5.5 Astaxanthin

Scientific Evidence

Several recent clinical trials emphasize the potential role of astaxanthin in enhancing eye health, as suggested by improvements observed in various ocular conditions such as age-related macular degeneration, diabetic retinopathy, glaucoma, and cataracts.

In one small RCT, a group of 15 patients received oral supplementation of astaxanthin (4 mg), zeaxanthin (1 mg), lutein (10 mg), vitamin C (180 mg), vitamin E (30 mg), zinc (22.5 mg), and copper (1 mg) daily for 12 months, versus a control group of 12 patients. The results showed that patients treated with supplementation showed selective improvement of retinal function compared with the control group.

The administration of an astaxanthin/lutein/zeaxanthin combination over a two-year period has been reported to improve visual acuity, contrast sensitivity, and vision-related functions.

Astaxanthin, due to its potent antioxidant activity, may influence choroidal neovascularization (CNV), a factor contributing to AMD, which is associated with oxidative stress and chronic inflammation in ocular tissues caused by the overexpression of VEGF.

The use of astaxanthin has been shown to reduce lens opacification in cataracts induced by prolonged steroid treatment or hyperglycemia, primarily in preclinical models.

Astaxanthin offers promising treatment prospects for combating ocular diseases and supporting eye health. However, to define optimal dosages and formulations, improving bioavailability and obtaining more data from clinical studies are essential, despite its broad safety profile.

Evidence strength: Preliminary to moderate. Most human data come from small RCTs, often involving astaxanthin in combination with other nutrients rather than as an isolated agent. Stronger evidence exists at the preclinical (in vitro and animal) level. Larger, well-powered human trials are lacking.

6. Herbs and Plant-Derived Ingredients

6.1 Bilberry (Vaccinium myrtillus L.)

Traditional Use

An anthocyanin complex from bilberry (Vaccinium myrtillus L.) fruit is widely used in Europe for medicinal purposes and as a dietary supplement in countries in East Asia, especially Japan. Bilberry anthocyanins have been reported to enhance night visual acuity and are used as a supplement to improve vision health.

Bilberry contains 15 types of low-molecular anthocyanin glycosides made up of a combination of five types of aglycones (cyanidin, delphinidin, malvidin, peonidin, and petunidin) and three types of monosaccharides (glucose, galactose, and arabinose). These 15 V. myrtillus anthocyanins (VMAs) serve as the main components of bilberry.

Bilberry fruit extract is believed to have anti-angiogenic properties that may help decrease blood-vessel leakage in AMD and diabetic retinopathy. Bilberry contains high concentrations of anthocyanosides that are said to maintain rhodopsin levels, the purple pigment used by the rods in the eye for night vision.

Scientific Evidence

A systematic review of placebo-controlled trials, cited in the NCBI Database of Abstracts of Reviews of Effects, systematically reviewed placebo-controlled trials of V. myrtillus-extracted anthocyanosides for evidence of positive effects on night vision. Searches identified 30 trials with outcome measures relevant to vision in reduced light, of which 12 were placebo-controlled. The 4 most recent trials were all randomized controlled trials (RCTs) and were negative in outcome. A fifth RCT and 7 non-randomized controlled trials reported positive effects on outcome measures relevant to night vision.

The hypothesis that V. myrtillus anthocyanosides improve normal night vision is not supported by evidence from rigorous clinical studies. There is a complete absence of rigorous research into the effects of the extract on subjects suffering impaired night vision due to pathological eye conditions.

Clinical studies of anthocyanin intake have shown improved dark adaptation, transient myopic shift, and improvement in retinal blood circulation in normal tension glaucoma patients. One 12-week RCT reported improvements in ciliary muscle function with standardized bilberry extract, and a small pilot study found that a combination of bilberry extract (600 mg) and fish oil over 3 months improved dry eye symptoms. Out of the four variables measured, OSDI score, non-invasive tear break-up time, and phenol red thread test showed notable improvements between the intervention and control groups, with mean scores passing the clinical dry eye cut-off values. This pilot study provided outcomes on the effect of 3-month dietary supplementation of bilberry extract and fish oil on signs and symptoms in adults with severe dry eye disease.

Negative outcomes in the night-vision trials were associated with more rigorous methodology, but also with lower dose levels and extracts from geographically distinct sources that may differ in anthocyanoside composition.

Evidence strength: Weak-to-moderate. The claim that bilberry improves normal night vision is not supported by the most rigorous RCTs. Some smaller or less rigorous trials showed positive effects. Evidence for accommodation, circulation, and dry eye is preliminary and from small samples. Further well-designed RCTs in populations with impaired vision are needed.

6.2 Ginkgo biloba

Traditional Use

Ginkgo biloba has a long history of use in traditional Chinese medicine, primarily for circulatory and cognitive health. Its flavonoid and terpenoid compounds have been studied in several European and Asian contexts for vascular and neuroprotective applications.

Scientific Evidence

Ginkgo biloba has been shown to possess antioxidant properties that help increase blood circulation in the optic nerve and reduce vasospasm and serum viscosity. A randomized, placebo-controlled trial of 27 patients with normal tension glaucoma reported an improvement in pre-existing visual field damage in some ginkgo-treated patients.

Two small human studies reported that supplementation with 80 mg twice daily or 240 mg once daily of Ginkgo biloba led to modest improvement in vision of individuals with macular degeneration.

A number of laboratory animal and cell culture studies have reported that Ginkgo biloba extracts have strong antioxidant as well as anti-inflammatory properties and provide protection against oxidative damage to retinal cells and mitochondria.

Evidence strength: Weak-to-preliminary for AMD. Some positive signal for glaucoma-related visual field damage from small RCTs. Preclinical evidence is more robust. No large-scale, well-powered RCTs establish Ginkgo biloba as effective for vision protection in the general aging population.

7. Dietary Patterns and Lifestyle Factors

7.1 Mediterranean Diet

Adherence to a Mediterranean diet, rich in vegetables, fruits, legumes, whole grains, and nuts, has been linked to a lower risk of both early and late AMD.

Based on available data, it is recommended that individuals with AMD increase their daily dietary intake of green leafy vegetables and consume oily fish at least twice a week. Furthermore, the Mediterranean diet has a beneficial effect on patients with AMD.

The interaction of monounsaturated fatty acids (MUFAs), constituents of olive oil, with AMD encompasses several processes, including reducing inflammation and oxidative stress. It is evident that the consumption of MUFAs, particularly olive oil, and adherence to the Mediterranean diet, provide a multitude of advantageous effects on human health.

7.2 Green Leafy Vegetables and Food Sources of Macular Carotenoids

Current evidence suggests that higher dietary intakes of lutein and zeaxanthin are likely to play an important role in protecting against AMD. Macular pigment optical density (MPOD), a measurement of the attenuation of blue light by the macular pigment, is linearly related to the amount of lutein and zeaxanthin in the macula.

The majority of studies have shown an age-dependent decrease in MPOD levels and a lack of MPOD in AMD compared to healthy controls. A 2016 meta-analysis of 20 randomized controlled trials found that lutein, zeaxanthin, and meso-zeaxanthin supplementation improves MPOD in both healthy subjects and in AMD patients in a dose-response manner.

7.3 Smoking Cessation

Smoking exhibits a dose-response relationship with AMD incidence, as demonstrated by multiple prospective cohort studies. It is the single most consistently identified modifiable lifestyle risk factor for AMD in the peer-reviewed literature, and is also associated with accelerated cataract formation.

7.4 UV Light Protection

Prolonged exposure to UV radiation from sunlight can increase the risk of cataracts. UV rays can damage the proteins in the lens and promote oxidative stress. A significant association has been demonstrated between cataract and glaucoma and exposure to sunlight, as well as physical inactivity.

7.5 Physical Activity

Physical inactivity accompanied by a low-grade inflammatory status has been identified as a significant risk factor of blindness, cataract, and glaucoma. A very significant association was also shown between blindness, cataract, glaucoma, and exposure to sunlight by profession.

Physical inactivity has been associated with an increased risk of early AMD and its progression, alongside other systemic conditions such as diabetes, hypertension, cardiovascular disease, and obesity.

7.6 Body Weight and Systemic Health

Age, smoking, cataract surgery, BMI, vascular diseases, hypertension, fibrinogen, atherosclerosis, high-density lipoprotein cholesterol (HDL-C), and blue light from smart devices are among the factors that might affect the development of AMD.

Although a number of studies have shown a link between cardiovascular risk factors and AMD, the roles of hypertension, atherosclerosis, high BMI, diabetes mellitus, higher plasma fibrinogen, and hyperlipidemia remain equivocal owing to inconsistent findings.

8. Summary of Evidence Strength by Nutrient/Ingredient

• Lutein + Zeaxanthin (combined with AREDS vitamins): Strong — large multicenter RCT (AREDS2, n=4,203); reduces AMD progression by ~26%; increases MPOD in meta-analyses of RCTs.
• Vitamins C + E + Zinc (AREDS formula): Strong — reduces AMD progression by ~25–28% in high-risk individuals in a large, long-term RCT.
• Omega-3 fatty acids (supplement): Weak-to-moderate — no added benefit over AREDS formula in AREDS2 RCT; observational data suggest dietary benefit; preliminary positive findings for dry eye.
• Astaxanthin: Preliminary — small RCTs in AMD show promise; preclinical evidence is stronger; optimal dose and formulation not established.
• Bilberry (V. myrtillus): Weak for night vision in normal subjects — most rigorous RCTs negative; some preliminary evidence for accommodation and dry eye. Traditional use is well-established in Europe and Asia.
• Ginkgo biloba: Preliminary — small RCTs suggest possible benefit for glaucoma-related visual field; insufficient large-scale evidence for AMD or lens health.
• Mediterranean dietary pattern: Moderate — multiple observational studies link adherence to reduced AMD risk; plausibly mediated by antioxidant and anti-inflammatory food components.

References

• NIH News in Health: Your Aging Eyes
• StatPearls – Presbyopia (NIH/NCBI Bookshelf)
• Grossniklaus et al., Anatomic Alterations in Aging and Age-Related Diseases of the Eye, IOVS 2013 (PMC)
• Preface: The Aging Eye – Normal Changes, Age-Related Diseases, and Sight-Saving Approaches, IOVS 2013 (PMC)
• Aging and Age-Related Diseases of the Ocular Lens and Vitreous Body, IOVS 2013 (PMC)
• National Institute on Aging – Aging and Your Eyes
• Age-Related Macular Degeneration – Nature Reviews (PMC)
• Age-Related Macular Degeneration: Epidemiology, Pathophysiology, Diagnosis, and Treatment (PMC)
• Chakravarthy et al., Clinical Risk Factors for AMD: A Systematic Review and Meta-Analysis, BMC Ophthalmology 2010 (PMC)
• NIH/NEI: Study Confirms Benefit of Supplements for Slowing AMD
• NIH News Release: AREDS2 Supplement Benefit Confirmed
• NIH National Eye Institute – About AREDS and AREDS2
• Chew et al., Long-term Outcomes of Adding Lutein/Zeaxanthin and Omega-3 to AREDS Supplements: AREDS2 Report 28 (PMC)
• The Effect of Lutein/Zeaxanthin Intake on Macular Pigment Optical Density: A Systematic Review and Meta-Analysis (PubMed)
• Lutein and Zeaxanthin — Food Sources, Bioavailability and Dietary Variety in AMD Protection (PMC)
• Lutein and Zeaxanthin Isomers in Eye Health and Disease (PMC)
• Lutein, Zeaxanthin and Meso-zeaxanthin Supplementation Associated with Macular Pigment Optical Density – Meta-analysis of RCTs (PMC)
• Lutein, Zeaxanthin, and meso-Zeaxanthin in the Clinical Management of Eye Disease (PMC)
• Intakes of Lutein, Zeaxanthin, and Other Carotenoids and AMD During 2 Decades of Prospective Follow-up (PMC)
• Oxidative Stress in Cataracts (PubMed)
• Oxidative Stress and Cataract Formation (PMC)
• Narrative Review on Dietary Components and Patterns and AMD, Nutrition Research Reviews (Cambridge)
• Modifiable Lifestyle Risk Factors and Strategies for Slowing AMD Progression (PMC)
• Global Burden of Smoking-Associated AMD: Spatiotemporal Trends 1990–2021, Tobacco Induced Diseases
• DARE Review: Anthocyanosides of Vaccinium myrtillus (Bilberry) for Night Vision: A Systematic Review of Placebo-Controlled Trials (NCBI Bookshelf)
• Therapeutic Effects of Anthocyanins for Vision and Eye Health (PMC)
• A 12-Week Randomized Trial of Bilberry Extract on Ciliary Muscle Contraction (PMC)
• Bilberry-Containing Supplements on Severe Dry Eye Disease: A 3-Month Pilot Analysis (PMC)
• Potential Properties of Natural Nutraceuticals and Antioxidants in Age-Related Eye Disorders, MDPI Life 2023
• The Role of Oral Supplementation for the Management of AMD: A Narrative Review (PMC)
• The Effect of a Mediterranean Diet on the Incidence of Cataract Surgery (PMC)
• Role of Mediterranean Diet, Tropical Vegetables, and Sunlight Exposure in Blindness, Cataract and Glaucoma (PMC)
• Beneficial Effects of a Lutein-Zeaxanthin Complex on Macular Pigment Optical Density Levels in Healthy Individuals with Prolonged Screen Time (PMC)